Title |
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
|
---|---|
Published in |
BMC Cancer, April 2016
|
DOI | 10.1186/s12885-016-2312-3 |
Pubmed ID | |
Authors |
E. Palmerini, R. L. Jones, E. Marchesi, A. Paioli, M. Cesari, A. Longhi, C. Meazza, L. Coccoli, F. Fagioli, S. Asaftei, G. Grignani, A. Tamburini, S. M. Pollack, P. Picci, S. Ferrari |
Abstract |
Few new compounds are available for relapsed osteosarcoma. We retrospectively evaluated the activity of gemcitabine (G) plus docetaxel (D) in patients with relapsed high-grade osteosarcoma and high-grade spindle cell sarcoma of bone (HGS). Patients receiving G 900 mg/m(2) d 1, 8; D 75 mg/m(2) d 8, every 21 days were eligible. Primary end-point: progression-free survival (PFS) at 4 months; secondary end-point: overall survival (OS) and response rate. Fifty-one patients were included, with a median age of 17 years (8-71), 26 (51 %) were pediatric patients. GD line of treatment: 2nd in 14 patients, ≥3rd in 37. 25 (49 %) patients had metastases limited to lungs, 26 (51 %) multiple sites. 40 (78 %) osteosarcoma, 11 (22 %) HGS. Eight (16 %) patients achieved surgical complete response (sCR2) after GD. Four-month PFS rate was 46 %, and significantly better for patients with ECOG 0 (ECOG 0: 54 % vs ECOG 1: 43 % vs ECOG 2: 0 %; p = 0.003), for patients undergoing metastasectomy after GD (sCR2 75 % vs no-sCR2 40 %, p = 0.02) and for osteosarcoma (osteosarcoma 56 % vs HGS 18 %; p = 0.05), with no differences according to age, line of treatment, and pattern of metastases. Forty-six cases had RECIST measurable disease: 6 (13 %) patients had a partial response (PR), 20 (43 %) had stable disease (SD) and 20 (43 %) had progressive disease (PD). The 1-year OS was 30 %: 67 % for PR, 54 % for SD and 20 % for PD (p = 0.005). GD is an active treatment for relapsed high-grade osteosarcoma, especially for ECOG 0 patients, and should be included in the therapeutic armamentarium of metastatic osteosarcoma. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 2% |
France | 1 | 2% |
Unknown | 63 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 13 | 20% |
Student > Ph. D. Student | 9 | 14% |
Student > Postgraduate | 8 | 12% |
Other | 5 | 8% |
Student > Master | 5 | 8% |
Other | 14 | 22% |
Unknown | 11 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 38 | 58% |
Biochemistry, Genetics and Molecular Biology | 4 | 6% |
Immunology and Microbiology | 3 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
Mathematics | 1 | 2% |
Other | 5 | 8% |
Unknown | 13 | 20% |